The gastrointestinal lymphoma can be classified in primary or secondary, and this is important regarding diagnosis and subsequent treatment. Primary gastrointestinal lymphoma of the rectum is rare and therefore lacks data in medical literature. Its incidence has been increasing and that fact may be related to a higher incidence in immunosuppressive therapy and immunosuppressive diseases (such as AIDS).
Metodology19 articles have been reviewed, searched online on the Scielo and PubMed databases. The goal was to increase data available regarding this pathology and improve its therapy.
DiscussionPrimary GI lymphoma of the rectum presents as hematochezia, rectal pain, change in bowel habits. PET/CT is the first choice exam to pursue investigation; however abdominal CT and MRI reveal sufficient information and are much more available in daily practice. Plasmablastyc lymphoma is an aggressive subtype and is usually associated with AIDS patients. There are no available treatment protocols for this specific type of lymphoma and colonic lymphoma’s therapy is usually used for this patient (such as ECHOP and CHOP).
ConclusionAs rare as this pathology is, this article aims to improve the available data and provide useful information regarding diagnosis and therapy.
O linfoma do TGI pode ser dividido entre primário e secundário, com importância diagnóstica e terapêutica. O linfoma primário de reto é patologia rara, pouco relatada em literatura médica. Sua incidência tem aumentado e possivelmente esse fenômeno esteja associado ao aumento no numero de pacientes com imunossupressão (seja por SIDA ou drogas imunossupressoras).
MetodologiaForam revisados 19 artigos nas bases de dados Scielo e PubMed, com o objetivo de aumentar o número de relatos dessa patologia e consequentemente expandir o conhecimento disponível, visando melhorar a terapêutica e, principalmente, o diagnóstico desse tipo de linfoma.
DiscussãoQuando o linfoma tem seu sítio primário no reto, as principais manifestações são sangramento, dor retal, tenesmo e mudança nos hábitos intestinais (diarreia ou constipação). O exame de investigação de escolha é o PET/CT, porém a TC e RNM fornecem as informações necessárias e são mais disponíveis na prática clínica. O linfoma plasmablástico é um subtipo bastante agressivo e associado aos pacientes com SIDA. Não existem ainda protocolos definidos para o tratamento do linfoma primário de reto, sendo optado por seguir a mesma terapêutica dos linfomas de cólon com esquemas EPOCH e CHOP.
ConclusãoPor se tratar de patologia rara e pouco descrita na literatura, espera-se que este relato contribua na formação de protocolos de tratamento específicos.
Primary gastrointestinal lymphoma is a rare condition, defined as lymphomas involving the Gastrointestinal Tract (GIT) or presenting with gastrointestinal symptoms. The lymphoma with secondary involvement of TGI is more commonly found.1,2 This differentiation guides the treatment.
Primary colonic lymphoma is rare and accounts for only 0.2 %‒0.4 % of all colon cancers, 10 %‒5 % of all primary gastrointestinal lymphomas and about 30 % of extra-nodal lymphomas.3,4 The most commonly affected sites are the stomach, followed by the small intestine and ileocecal transition.5
The most common colonic location is the caecum (70 %), followed by the rectum and ascending colon.6
Intestinal lymphomas can be classified into B-cell lymphomas (85 %) and T-cell lymphomas (15 %). Among B-cell lymphomas, mantle cell lymphoma has a worse prognosis, whereas Mucosa-Associated Lymphoid Tissue (MALT) lymphomas have a better prognosis than other B-cell tumors.6
Studies suggest that the incidence of primary gastrointestinal lymphoma has increased,7 which may be explained by the presence of immunosuppression, either due to mediated Acquired Immunodeficiency Syndrome (AIDS), by an increase in the prescription of immunosuppressive drugs used after transplantation or associated with treatments for autoimmune diseases.7,8 Drugs related to increased incidence of lymphomas include thiopurines (azathioprine and 6-mercaptopurine),9,10 and, to a lesser extent, the anti-Tumor Necrosis Factor (anti-TNF) therapy.11
Methodology and objectivesTotally, 19 articles retrieved from the Scielo and PubMed databases were reviewed in order to increase the number of reports regarding this pathology and consequently expand the available knowledge, aiming at improving the therapy and, particularly, the diagnosis of this type of lymphoma.
Case reportMale patient, 19-year-old, treated at the HNSC emergency department, with a history of anal bleeding (bright red blood) for a year, associated with pain and anal tumor for a month, who had undergone at least two attempts to drain the lesion. Prior to hospitalization, he had hypothyroidism, clinically treated with hormone replacement, in addition to depression and irregular psychiatric treatment. Anal inspection revealed right posterolateral perianal lesion, about 6cm in diameter, hardened, without drainage of secretion, but with incisions in the central portion. The overlying skin had hemorrhagic suffusion (Figs. 1 and 2). Rectal examination revealed a hypotonic sphincter in a 3cm anal canal with apparent hardened lesion in the right posterior and lateral anal canal, adjacent to the described perianal tumor lesion. No blood or pus. Mild anemia was evidenced during the initial examination. A pelvic MRI scan (Fig. 3) demonstrated a 11.2×7.6×7.4cm tumor extensively invading the right levator ani muscles (mainly the puborectalis). In the right intergluteal sulcus there was a small area with fluid inside (1.2×1.0), with a probable fistulous path to the skin. The prostate and seminal vesicles were displaced anteriorly, without invasion and preserving the capsule contour. Defining cleavage plan with the sacrum; prominent bilateral inguinal lymph nodes, especially to the right (largest=1.1×0.9); absence of lymph node enlargement or free fluid in the pelvis. Subsequently, an incisional biopsy of the lesion was performed under general anesthesia, with anatomopathological results compatible with large cell non-Hodgkin’s lymphoma and immunohistochemical profile compatible with immunophenotype B lymphoma, plasmablastic lymphoma, positive for CD10, CD20, CD138, ki-67, Bcl-2 and negative for EBV. Also during the investigation, he was diagnosed with HIV infection, with significant immunosuppression (CD4 37 and CV 541,213 copies).
Afterwards, the patient was transferred to the hematology department for therapeutic planning and, during this period, he presented with compressive urinary tract symptoms (with doxazosin response) and psychiatric decompensation, requiring antipsychotic drugs due to the high risk of suicide. After a bone marrow biopsy negative for lymphoma infiltration, chemotherapy with Etoposide+Doxorubicin+Vincristine (EPOCH) was started. Antiretroviral Therapy (ART) was started with an alternative regimen (abacavir+lamivudina+dolutegravir), associated with prophylactic trimethoprim-sulfamethoxazole.
After the second cycle of chemotherapy, a control CT scan was performed, which showed complete regression of the rectal lesion. The chemotherapy regimen was maintained until the fourth cycle and then PET-CT was performed, which demonstrated absence of areas of abnormal metabolic activity characteristic of active lymphoproliferative disease and absence of parietal thickening or abnormal metabolic increase in the rectum (Lugano score 1).
DiscussionThe clinical, radiological, and endoscopic features of the primary gastrointestinal lymphoma are nonspecific, which may hinder the diagnosis, making the clinical picture often indistinguishable from other colon diseases, whether neoplastic or inflammatory. When lymphoma has its primary site in the rectum, the main manifestations are bleeding, rectal pain, tenesmus and change in bowel habits (diarrhea or constipation).12
PET/CT is the image of choice for analysis of mass, area of stenosis, and lymph node involvement,13 but imaging tests such as pelvic CT and MRI are often sufficient to identify the lesion and are more available in clinical practice. Colonoscopy can show variable mucosal involvement, whether it is a mass, ulceration or infiltration,14 and allows biopsies for histopathological diagnosis.
Plasmablastic Lymphoma (PBL) is classified by the World Health Organization as a type of mature B-cell lymphoma that expresses plasma antigens (CD38, CD138, MUM1) and common B-cell antigens (CD20, CD19, PAX5) with negative CD45.15,16 While its pathogenesis is not yet fully understood, it has been shown that Epstein Barr Virus (EBV) is present in most cases. In addition, an association with MYC gene rearrangement has been found in a small percentage of cases.4 PBL lymphoma was initially identified in the oral cavity of patients with Human Immunodeficiency Virus (HIV) and approximately 80 % of PBL cases are associated with this HIV-positive population.17 PBL has also been found in areas outside the oral cavity, favoring sites such as the Gastrointestinal (GI) tract, lymph nodes, and skin.18 The GI tract is one of the most common extranodal sites. PBL is considered an aggressive lymphoma with a median overall survival of 14 months.17,18 Regarding treatment, there are no exclusive protocols to guide the extraperitoneal rectal lymphoma management, and cases are treated following the guidelines of intraperitoneal rectal lymphoma. Although both CHOP and EPOCH are considered common therapeutic choices, standard therapy or treatment guidelines have not yet been established. Autologous transplantation is considered optional and tends to have a good outcome, but there is little experience with this treatment.19 Surgical treatments are rarely needed and are usually indicated in case of complications.
ConclusionPrimary gastrointestinal lymphomas are themselves rare pathologies, with extraperitoneal rectal lymphoma being an even rarer form. Primary gastrointestinal lymphomas are rare pathologies in themselves, with extraperitoneal rectal lymphoma being an even rarer form. It represents a diagnostic challenge and lacks specific protocols to guide therapy. With this report, it is expected to add data to the currently available literature.
Conflicts of interestThe authors declare no conflicts of interest.
